Industries de la santé
20 Mars 2012
Significantly improved cardiac function, smaller infarct size with greater regional left ventricle wall thickness and the pronounced stimulation of new vessels formation were observed in animals treated with PLX cells |HAIFA, ISRAEL, March 20, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that its PLacental eXpanded (PLX) cells, tested in a preclinical...
Plus d'articles...
- Nouveau départ dans la prise en charge des Tumeurs Neuroendocrines d’origine pancréatique
- Non-Controversial Approach to Stem Cell Research: Pluristem Activities Recap
- Pluristem Announces Positive 12-Month Data from the Use of PLX-PAD for the Treatment of Critical Limb Ischemia
- Novartis Pharma :AMM européenne pour Votubia®